| Drug Name: | Nifedipine (21829-25-4) |
|---|---|
| PubChem ID: | 4485 |
| SMILES: | CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC |
| InchiKey: | HYIMSNHJOBLJNT-UHFFFAOYSA-N |
| Therapeutic Category: | Calcium Channel Blockers, Cardiovascular Agents, Membrane Transport Modulators, Reproductive Control Agents, Tocolytic Agents, Vasodilator Agents |
| Molecular Weight (dalton) | : | 346.339 |
| LogP | : | 2.1756 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 107.77 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Imatinib (152459-95-5) | Abdominal Pain | Synergistic | imatinib may inhibit the metabolism of nifedipine, leading to an increase in its effects on lipids, leading to an increase in biliary secretion and gallstone development. | Clinical drugs that interact with St John's wort and implication in drug development |
| Imatinib (152459-95-5) | Nausea | Synergistic | imatinib may inhibit the metabolism of nifedipine, leading to an increase in its effects on lipids, leading to an increase in biliary secretion and gallstone development. | Clinical drugs that interact with St John's wort and implication in drug development |
| Imatinib (152459-95-5) | Vomiting | Synergistic | imatinib may inhibit the metabolism of nifedipine, leading to an increase in its effects on lipids, leading to an increase in biliary secretion and gallstone development. | Clinical drugs that interact with St John's wort and implication in drug development |
| Prazosin (19216-56-9) | Blood Pressure Falls Down Sharply | Synergistic | Not Understood | Nifedipine-prazosin interaction in patients with essential hypertension |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Side Effects | Adenosylhomocysteinase (O43865) | Inhibition of an enzyme involved in transmethylation reactions was observed in patients during arabinoside(ara-A) therapy,which could contribute to the side effects and antiviral properties of ara-A [ ADR Type 1 ] | Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Grapefruit Juice | Hypotension | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
| Grapefruit Juice | Peripheral Edema | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category